Increasing data indicate that inflammation and alterations in glutamate neurotransmission
are two novel pathways to pathophysiology in mood disorders. The primary goal of this …

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …

The N-methyl-d-aspartate (NMDA) receptor antagonist ketamine is one of the most attractive
antidepressants for treatment-resistant major depressive disorder (MDD). Ketamine (or RS …

Major depressive disorder (MDD) is associated with significant morbidity and mortality.
Findings from preclinical and clinical studies suggest that psychiatric illnesses, particularly …

Objective: Suicide, a major cause of death worldwide, has distinct biological underpinnings.
The authors review and synthesize the research literature on biomarkers of suicide, with the …

Neuroimaging and postmortem studies of subjects with major depressive disorder (MDD)
reveal smaller hippocampal volume with lengthening duration of illness. Pathology in …

The increasing number of individuals with comorbidities poses an urgent need to improve
the management of patients with multiple co-existing diseases. Among these comorbidities …

Background: Brain-derived neurotrophic factor (BDNF) and its receptor, tropomyosin-related
kinase B (TrkB), signaling represent potential therapeutic targets for major depressive …

Major depressive disorder (MDD) is a disabling medical condition associated with significant
morbidity, mortality and public health costs. However, neurocircuitry abnormalities …

The N-methyl-D-aspartate antagonist ketamine has rapid antidepressant effects in patients
with treatment-resistant major depression (TRD); these effects have been reported to last for …